MAPK3 and liver cancer: Fisetin has been known to prevented from the liver cancer cell line proliferation in vivo study of mice via inhibiting the migration and invasion, inducing apoptosis, activating caspase‐3, suppressing TGF‐β1, lowering epithelial–mesenchymal transition (EMT), ameliorating cancer progression, enhancing survival time, and down‐regulating the expressions of p‐ERK1/2, vascular endothelial growth factor receptor 1(VEGFR1), p38, and pJNK, respectively (Liu, Long, Miao, Liu, & Yao, 2017).